[ad_1]
Biogen’s Alzheimer’s Drug Could be Expensive
Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s reported on Friday, citing data from The Institute for Clinical and Economic Review. The…
on TipRanks.com
[ad_2]
[ad_1]
Biogen’s Alzheimer’s Drug Could be Expensive
Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s reported on Friday, citing data from The Institute for Clinical and Economic Review. The…
on TipRanks.com
[ad_2]